Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)

Sutro Biopharma has reported Change in Accured Expenses for 9 years, with the latest figure at -$79000.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 89.38% year-over-year to -$79000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 148.3% YoY) and the FY2025 annual result came in at $3.6 million, up 148.3% from the prior year.
• Change in Accured Expenses eased to -$79000.0 in Q4 2025 per STRO's latest filing, from $4.8 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $20.7 million in Q4 2023 and troughed at -$6.7 million in Q2 2025.
• A 5-year average of $1.7 million and a median of $58000.0 in 2021 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1249.74% in 2022, down 2150.56% in 2022.
• Over 5 years, Change in Accured Expenses stood at $5.2 million in 2021, then jumped by 45.1% to $7.6 million in 2022, then jumped by 172.68% to $20.7 million in 2023, then sank by 103.59% to -$744000.0 in 2024, then soared by 89.38% to -$79000.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$79000.0, $4.8 million, and -$6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.